Preclinical Data Demonstrates SonoTran® Increased Delivery and Efficacy of ADCT-601 in Human Renal Cancer Model

Data from collaboration with ADC Therapeutics presented at the EORTC-NCI-AACR Symposium showed SonoTran® increased potency of ADCT-601 by 3.3 times

OXFORD, UK , October 31, 2022 / B3C newswire / -- OxSonics Therapeutics, a clinical-stage company focused on transforming cancer treatment through SonoTran®, its ultrasound-based drug delivery platform, today announces positive preclinical efficacy data for SonoTran® in combination with ADC Therapeutics’ (“ADCT”) antibody drug conjugate (“ADC”), ADCT-601. The data was presented in a poster entitled ‘Ultrasound-induced cavitation enhances therapeutic efficacy of AXL-targeting ADC leading to improved survival in a human xenograft model of renal cancer’ at the EORTC-NCI-AACR (ENA) Symposium, Barcelona, Spain on 28 October by Dr Massimo Masiero, Senior Development Scientist, OxSonics.

ADCs are targeted medicines that combine a monoclonal antibody with an anti-cancer drug, which enables the specific killing of cancer cells whilst reducing the chances of systemic toxicity. In recent years, they have proven to be a promising new therapeutic class, particularly for the treatment of hematological malignancies and breast cancer. However, given their relatively large size, it is difficult for them to penetrate into and throughout solid tumor tissue. SonoTran®, OxSonics’ proprietary technology platform, is being developed to enhance the delivery and improve the efficacy of systemically administered oncology drugs. It combines innovative Particles that are co-administered independently with an anti-cancer drug, which are activated by a novel ultrasound device at the tumor site, creating a localised pumping effect that increases the delivery and penetration of the anti-cancer drug throughout the tumor.

The data presented in the poster was a collaboration between OxSonics Therapeutics and ADCT to assess the ability of SonoTran® to enhance the efficacy of ADCT-601 in a human xenograft model of renal cancer. ADCT-601 is currently in phase 1b clinical development in patients with selected advanced solid tumors.

The study evaluated two doses of ADCT-601, one known to be efficacious (1mg/kg) when administered alone and one that is ineffective alone (0.3mg/kg). During the study, the lower dose was administered with and without SonoTran®. The results showed the mice treated with 0.3mg/kg ADCT-601 + SonoTran® had significant tumor growth delay, which led to a significant improvement in survival compared to the control groups. The efficacy of the 0.3mg/kg ADCT-601 + SonoTran® was equivalent to that seen with 1mg/kg ADCT-601, indicating that the SonoTran® combination enhanced potency by 3.3 times.

SonoTran® is currently being evaluated in a phase I/IIa proof of concept clinical study in patients with metastatic colorectal cancer with liver metastases.

Christian Coviello, Chief Technology Officer, OxSonics, commented: “The data presented at ENA is further evidence of the potential of SonoTran® to increase the delivery and efficacy of a wide variety of anti-cancer treatments. It follows data presented at IOVC last week, which demonstrated SonoTran’s ability to increase the delivery and efficacy of a systemically administered oncolytic virus. We are particularly encouraged by the significant increase in the potency of ADCT-601 when combined with SonoTran®, which was greater than threefold. This indicates SonoTran’s potential to increase the therapeutic index of anti-cancer drugs by enhancing efficacy at lower systemic doses.”

The poster is available on the Company's website at: Scientific Publications - OxSonics Therapeutics

About The EORTC-NCI-AACR Symposium
Hosted by the European Organisation for Research and Treatment of Cancer (EORTC), the National Cancer Institute (NCI) and the American Association for Cancer Research (AACR), ENA is the drug development and translational research meeting, focusing on preclinical and phase I studies, enabling and facilitating in-depth scientific discussions on the latest developments in targets and drugs. It attracts academics, scientists and pharmaceutical industry representatives from across the globe to discuss the latest innovations in drug development, target selection and the impact of new discoveries in molecular biology.

About OxSonics Therapeutics
OxSonics is a clinical-stage therapeutics company, transforming cancer treatment by harnessing its first-in-class, proprietary technology platform SonoTran® to enhance the delivery and improve the efficacy of oncology drugs.
Current oncology drugs are restricted by their poor ability to penetrate solid tumors.
SonoTran® is being developed to provide a step-change in the therapeutic index of the drugs without the development costs or delays associated with drug reformulation. It combines Particles that are co-administered independently with an anti-cancer drug, and activated by a novel ultrasound device, creating a localised pumping effect that increases the delivery and penetration of the anti-cancer drug throughout the tumor. SonoTran® is designed to increase the dose and distribution of anti-cancer agents within solid tumours, thereby increasing the efficacy and/or reducing the toxicity of these agents across the majority of the most challenging solid tumor cancers.
The approach has been specifically designed to fit seamlessly into existing oncology clinical workflows, and has the major advantage of enabling healthcare professionals to see-as-they-treat by providing visualisation on-screen and in real time.
SonoTran® is currently being evaluated in a phase I/IIa proof of concept clinical study in patients with metastatic colorectal cancer with liver metastases.
The SonoTran® drug delivery platform is based on ground-breaking technological advances, originally invented at the University of Oxford’s Institute of Biomedical Engineering.
OxSonics is based in Oxford in the UK.

Contacts

OxSonics Therapeutics
Christian Coviello, Chief Technology Officer
+44 (0)1865 784777

Walbrook PR (Media enquiries)
Stephanie Cuthbert / Phillip Marriage
+44 (0) 20 7933 8780 or +44 (0)7796 794 663
oxsonics@walbrookpr.com

Keywords: Animals; Kidney Neoplasms; Immunoconjugates; Antibodies, Monoclonal; Drug Delivery Systems; Drug Compounding; Ultrasonography; Technology; Clinical Conference; Biological Products; UK

Published by B3C newswire